Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic CancerMolecular Cancer Therapeutics, 2010
- Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling PathwaysMolecular Cancer Research, 2010
- EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic CancerAnnals of Surgical Oncology, 2009
- An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancerSurgery, 2009
- Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signalingLaboratory Investigation, 2009
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Investigational New Drugs, 2008
- Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastomaNeuro-Oncology, 2007
- Pancreatic cancer–associated stroma productionThe American Journal of Surgery, 2007
- Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib MesylateClinical Cancer Research, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006